Progyny, Inc. (NASDAQ: PGNY) is a Healthcare company in the Medical - Healthcare Plans industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
27.13
+0.12+0.44%
TA
Loading chart...
Snapshot
| Index | - | P/E | 29.49 | EPS (ttm) | 0.92 | Insider Own | 19.76% | Shs Outstand | 78.33M | Perf Week | -0.80% |
| Market Cap | 2.13B | Forward P/E | 17.85 | EPS next Y | 1.52 | Insider Trans | -0.36% | Shs Float | 71.73M | Perf Month | 6.27% |
| Enterprise Value | 1.91B | PEG | 2.73 | EPS next Q | 0.51 | Inst Own | - | Short Float | 6.21% | Perf Quarter | 4.03% |
| Income | 78.00M | P/S | 1.62 | EPS this Y | 39.80% | Inst Trans | - | Short Ratio | 3.59 | Perf Half Y | 49.23% |
| Sales | 1.31B | P/B | 4.69 | EPS next Y | 18.19% | ROA | 10.98% | Short Interest | 4.45M | Perf YTD | 5.65% |
| Book/sh | 5.78 | P/C | 8.97 | EPS next 5Y | 10.82% | ROE | 15.98% | 52W High | 33.07 -17.96% | Perf Year | 25.43% |
| Cash/sh | 3.03 | P/FCF | 9.83 | EPS past 3/5Y | 29.40% 6.70% | ROIC | 15.32% | 52W Low | 16.10 68.51% | Perf 3Y | -23.14% |
| Dividend Est. | - | EV/EBITDA | 15.16 | Sales past 3/5Y | 17.88% 30.16% | Gross Margin | 24.57% | Volatility | 1.96% 2.69% | Perf 5Y | -53.48% |
| Dividend TTM | - | EV/Sales | 1.46 | EPS Y/Y TTM | 61.40% | Oper. Margin | 8.55% | ATR (14) | 0.80 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.14 | Sales Y/Y TTM | 12.34% | Profit Margin | 6.00% | RSI (14) | 49.95 | Recom | 2.30 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.14 | EPS Q/Q | 80.00% | SMA20 | 2.17% | Beta | 1.00 | Target Price | 35.50 |
| Payout | 0.00% | Debt/Eq | 0.05 | Sales Q/Q | 5.41% | SMA50 | -4.67% | Rel Volume | 2.53 | Prev Close | 27.01 |
| Employees | 846 | LT Debt/Eq | 0.05 | Earnings | Nov 05 | SMA200 | 12.19% | Avg Volume | 1.16M | Price | 27.13 |
| IPO Date | Oct 25, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 7.54% 0.42% | Net Debt/EBITDA | -0.99 | Volume | 2,942,356 | Change | 0.44% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-08-26 | Reiterated | Jefferies | Buy | $30 → $33 |
| Aug-20-26 | Initiated | Wells Fargo | Overweight | $37 |
| Aug-13-26 | Reiterated | Truist Securities | Buy | $28 → $36 |
| Aug-12-26 | Reiterated | Barclays | Equal Weight | $34 → $30 |
| Aug-07-26 | Reiterated | Canaccord Genuity | Buy | $36 → $35 |
| Jul-28-26 | Downgrade | Barclays | Overweight → Equal Weight | $27 → $34 |
| Jul-24-26 | Reiterated | BTIG | Buy | $41 → $40 |
| Jul-22-26 | Reiterated | Leerink Partners | Outperform | $30 → $38 |
| Jul-21-26 | Reiterated | Canaccord Genuity | Buy | $30 → $36 |
| Jul-13-26 | Reiterated | Keybanc | Overweight | $32 → $35 |
Latest News· Times ET
Sep-18-26
Sep-17-26
Sep-17-2607:45AM
Sep-15-26
Sep-15-2609:15AM
Sep-09-26
Sep-09-2606:55AM
Sep-05-26
Sep-03-26
Sep-02-26
Sep-02-2612:51AM
12:13AM
Aug-26-26
Aug-26-2610:30PM
Aug-25-26
Aug-25-2611:51PM
06:51AM
Aug-24-26
Aug-20-26
Aug-20-2606:08AM
Aug-18-26
Aug-16-26
Company
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,311 | 1,289 | 1,167 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 989 | 984 | 914 | — | — | — | — | — | — | |
| Gross Profit | 322 | 304 | 253 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 210 | 219 | 186 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | 112 | 85 | 67 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 10 | 16 | — | — | — | — | — | — | |
| Net Income Before Taxes | 120 | 95 | 83 | — | — | — | — | — | — | |
| Income Taxes | 41 | 37 | 29 | — | — | — | — | — | — | |
| Consolidated Net Income | 78 | 59 | 54 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 78 | 59 | 54 | — | — | — | — | — | — | |
| Net Income | 78 | 59 | 54 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.97 | 0.68 | 0.59 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.97 | 0.68 | 0.59 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.92 | 0.65 | 0.57 | — | — | — | — | — | — | |
| EBITDA | 126 | 100 | 86 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 29.49 | 39.51 | 30.26 | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.61 | 1.69 | 1.35 | — | — | — | — | — | — | |
| Gross Margin | 24.56 | 23.58 | 21.68 | — | — | — | — | — | — | |
| Operating Margin | 8.54 | 6.59 | 5.74 | — | — | — | — | — | — | |
| Net Margin | 5.95 | 4.58 | 4.63 | — | — | — | — | — | — | |
| Shares Outstanding | 78 | 85 | 91 | — | — | — | — | — | — | |
| Market Capitalization | 2,116 | 2,183 | 1,570 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| GORDON KEVIN K | Director | Sep 10 '26 | Sale | 27.53 | 23,000 | 633,216 | 6,792 | Sep 18 |
| GORDON KEVIN K | Director | Sep 10 '26 | Option Exercise | 13.00 | 22,000 | 286,000 | 28,792 | Sep 14 |
| Cummings Melissa B | Chief Operating Officer | Jul 14 '26 | Sale | 31.60 | 2,244 | 70,910 | 69,934 | Jul 16 |
| Swartz Allison | EVP, GC | Jun 04 '26 | Sale | 25.08 | 599 | 15,023 | 82,378 | Jun 05 |
| Livingston Mark S. | CHIEF FINANCIAL OFFICER | Jun 04 '26 | Sale | 25.50 | 2,517 | 64,184 | 74,688 | Jun 05 |
| Swartz Allison | EVP, GC | Jun 03 '26 | Sale | 25.02 | 1,199 | 29,999 | 83,316 | Jun 05 |
| Swartz Allison | EVP, GC | May 28 '26 | Sale | 25.46 | 2,398 | 61,053 | 85,191 | Jun 01 |
| GORDON KEVIN K | Director | May 27 '26 | Sale | 24.99 | 5,500 | 137,445 | 9,318 | May 29 |
| Livingston Mark S. | CHIEF FINANCIAL OFFICER | May 20 '26 | Sale | 25.50 | 8,275 | 211,013 | 79,063 | May 21 |
| Cummings Melissa B | Chief Operating Officer | May 19 '26 | Sale | 25.00 | 9,578 | 239,450 | 73,371 | May 21 |
| Swartz Allison | EVP, GC | Mar 04 '26 | Sale | 17.54 | 599 | 10,506 | 88,941 | Mar 06 |
| Swartz Allison | EVP, GC | Mar 03 '26 | Sale | 17.40 | 4,657 | 81,030 | 89,879 | Mar 04 |
| Swartz Allison | EVP, GC | Mar 02 '26 | Sale | 17.27 | 2,199 | 37,977 | 97,378 | Mar 04 |
| Livingston Mark S. | CHIEF FINANCIAL OFFICER | Dec 11 '25 | Sale | 25.50 | 459 | 11,705 | 46,983 | Dec 15 |
| Swartz Allison | EVP, GC | Dec 04 '25 | Sale | 24.59 | 530 | 13,033 | 72,719 | Dec 08 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.